Our Speakers
The Future of Healthcare: Embracing AI While Ensuring Universal Access
Embracing the potential of AI in healthcare promises unprecedented advances in diagnosis, treatment, and patient care. However, the journey from innovation to real-world application faces significant market access barriers. This talk delves into the complexities of integrating AI-driven solutions in the global healthcare landscape. We'll explore strategies for overcoming regulatory, economic, and ethical challenges, ensuring that these transformative technologies benefit all, irrespective of market dynamics.
Henry Jonckheere, Administrator MAEVH sas
Market access for AI driven solutions in healthcare: a European landscape
We'll explore the European market access landscape for AI driven solutions, the requirements and barriers to convince health authorities and payers of the therapeutic and economic value of the solutions so that it can benefit patients and the healthcare system in a timely manner.
Marc Czarka, MD, FBCPM
Cooperations with Saudi Arabian / GCC Life Sciences Companies – Opportunities & Threats
Benefits of cooperations with Life Sciences Companies in these markets
What can be achieved beyond Licensing and Distribution Agreements
Types of Cooperation
Co-Development
CDMO agreements
Strategic Partnerships
Mutual direct investments
Cultural, technical and legal hurdles
Prerequisites of a European partner
Technical deficiencies in the markets
How can VINC support your endeavors
Khalid Alkharfy, Thomas Kern, Manfred Stadler, VINC ADVISORY
The new EU pharma regulation reforms: What to expect and what’s in store for SMEs?
A change is always desired to implement new ideas.
So is the aim of the upcoming pharmaceutical legislation update. It is expected that the updated regulations will support and enhance innovation and ensure timely and equitable access to medicines. Another objective of the reform is to enhance security of supply and address shortages through specific measures. In this session, we will learn what is in favour of SME companies and what could pose a challenge?
Parminder Kaur, Managing Director, RegPak BioPharma Consulting
API Cannabidiol of Trigal Pharma for medical use : Properties and Perspectives
Trigal Pharma understands its role as a pharmaceutical company providing scientific evidence for Cannabidiol
as active pharmaceutical ingredient (API) through controlled clinical trials in various indications, regulatory and
marketing expertise and support to global manufacturers and producers of natural CBD for medicines and cosmetics
Eberhard Pirich, CEO, Trigal Pharma
The changing face of Global Pharmacovigilance
The only constant in Life is Change
Staying on top of the global regulatory requirements for drugs; devices; combination products and even cosmetics can mean the difference between compliance and fines for breaking the rules.
This talk covers some of the major changes that we have been guiding clients through as they expand their portfolios into other countries.
Dr Graeme Ladds B.Sc (Hons); PhD; MTOPRA; DIA; RQA, Director, PharSafer ltd
Innovative B2B solutions in the field of medical devices and food supplements. A project update from Lisbon 2023
Currently, the healthcare market is experiencing a significant demand for innovation that must align with the strictest local and international regulations. Innovative products require more time and investment for their development, research, clinical studies, intellectual property protection and regulatory strategy which can slow down your business. Metis offers highly innovative products for selected and demanding partners who want to speed up and qualify their business. Metis Healthcare is your partner in R&D, regulatory affairs and communication for your new products.
Prof. Cristiano Rumio, Head of innovation, Metis HealthCare
VectorB2B - Simplifying Drug Discovery and Development For You
VectorB2B provides 360º integrated services covering the entire supply chain from early discovery to clinical study (including post-marketing surveillance) in a smooth and efficient process. In addition to internal teams, VectorB2B also relies on a trusted network of renowned academic institutions and pharmaceutical companies. VectorB2B is a one-stop shop for your needs in Discovery, Toxicology, CMC, Clinical trials and Repurposing. VectorB2B services span multiple therapeutic areas and classes of molecules, offering the scientific expertise and technical capabilities required to support projects from target identification all the way through regulatory submission and clinical trial management, helping their customers improving product life cycle management.
Sofia Corte-Real, Head of Science, Vector B2B
Unleashing the potential of SMEs through alliances
In rapidly changing geopolitical situation pharmaceutical industry faces multiple challenges. Escalating costs result in the high cost of research and development, coupled with stringent regulatory requirements, all these factors drive up the price of pharmaceuticals. This results in expensive medications and reduced accessibility, which can burden healthcare systems and limit patient access to essential treatments.
SMEs should join forces to face those circumstances and therefore Will Pharma strongly believes that through alliances or partnerships, pharmaceutical companies can pool their expertise and resources. By doing so they can combine their knowledge, experience, and ideas and fast-track the drug development process.
Maurienne Will, CEO, Will Pharma
Unolab Manufacturing, S.L is a global CDMO, specialized in production of sterile unit-dose packaging, using Blow-Fill_Seal technology (BFS Bottelpack)
Our global CDMO service:
Formulation & manufacturing process development & transfer
Analytical methods development, transfer & validation
Scale up & Industrial process manufacturing
Regulatory support
Mayte Talavera, Commercial Director, Unolab Manufacturing
From “Start-up” to an “Emerging Specialty Company
What needs a SMC to grow from a Belgian “start-up”, to become an international “Emerging Specialty Company”: diversification by Partnerships, Territories, Products and R&D
Jan Van der Auwera, Business Development Manager, Colepharma